These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Results of a phase I clinical trial of "theraphthal + ascorbic acid" catalytic system].
    Author: Garin AM, Gorbunova VA, Gershanovich ML, Manziuk LV, Borodkina AG, Breder VV, Karmanovskaia OB, Zubrikhina GN, Madzhuga AV, Zimakova NI, Trapeznikov NN.
    Journal: Vopr Onkol; 2001; 47(6):676-9. PubMed ID: 11826487.
    Abstract:
    Phase-I clinical studies of teraphtal and a "teraphtal + ascorbic acid" catalytic system have been completed. The dose-limiting toxicity and maximum tolerable dose were not reached even at the end of maximal dose trials. No side-effects characteristic of antitumor cytostatic drugs were registered. The gravest side-effect ever recorded was a collapse which could not be linked to teraphtal dosage and was probably caused by hypersensitivity to the drug. The drug was recommended for phase II trials.
    [Abstract] [Full Text] [Related] [New Search]